Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Eli Lilly to widen its...

    Eli Lilly to widen its drug portfolio

    Written by savita thakur thakur Published On 2016-04-13T15:39:43+05:30  |  Updated On 13 April 2016 3:39 PM IST
    Eli Lilly to widen its drug portfolio

    Chennai : Global pharma major Eli Lilly will widen its therapeutic drug portfolio to include pain management and others while it would launch one diabetic and cancer drug in India, said a top official in the Indian subsidiary.


    "We will launch one diabetic and oncology drug soon. Out of around 50 products under various stages of trials, seven are undergoing phase 3 trials," Edgard Olaizola Story, managing director India, Eli Lilly and Company (India) Pvt. Ltd., told reporters here on Tuesday.

    He was here to launch Eli Lilly new once-a-week single dose diabetic injectible drug Trulicity.

    According to him, a major portion of the company's revenue is from diabetic drug sales and the balance is from sales of drugs for cancer, growth hormones, osteoporosis and others.

    Story said in two-three years few more cancer drugs will be launched and the company will also get into pain management and other segments.

    "One of our cancer drugs is under regulatory approval. We may get into stomach cancer segment. Currently, we are into lung cancer segment," said Tarun Puri, medical director.

    Speaking about the company's new once-a-week single dose diabetic injection Trulicity, Story said the drug is imported from the US and is priced Rs.2,499 per injection.

    He said India is one of the largest market for diabetes drugs and the company's new drug is convenient for Type 2 diabetic patients.

    Story said the India diabetic drug market is estimated at around $1 billion and the share of injectable is around $200-250 million with balance commanded by oral drugs.

    He said India is amongst the first few countries in the world and third in Asia where Trulicity a prescription drug has been launched.

    It should be used as an adjunct to diet and exercise, Story added.
    cancerdiabeticdrug portfolioEdgard Olaizola StoryEli Lillygrowth hormonesosteoporosisTarun PuriType 2 diabetic
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok